VIDEO: Toripalimab/axitinib provides longer PFS than sunitinib in advanced kidney cancer
MADRID — Treatment with toripalimab plus axitinib resulted in significantly longer PFS than treatment with sunitinib in patients with previously untreated advanced kidney cancer, according to a presentation from ESMO Congress.
In a video interview, Tian Zhang, MD, genitourinary oncologist at UT Southwestern Medical Center and member of the Kidney Cancer Association's Medical Steering Committee, discussed this randomized, open-label, phase 3 study (RENOTORCH), which examined toripalimab (Junshi Biosciences) combined with axitinib (Inlyta, Pfizer) versus sunitinib (Sutent, Pfizer) in first-line treatment of advanced renal-cell carcinoma in China.
Although VEGF inhibitor/immunotherapy combinations have been used in the U.S. and throughout the world, China does not yet have an approved indication of a VEGF/IO combination, according to Zhang.
“This — when it becomes approved in China — will become the first VEGF/IO combination for many kidney cancer patients in China. I think that’s very exciting for, perhaps, the world’s largest market in a single country for kidney cancer,” she told Healio.
Reference:
- Sheng X, et al. Abstract 18820. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Read more from Take Homes in Renal Cell Carcinoma
View allRead more about